153 related articles for article (PubMed ID: 10515673)
1. Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group.
Bjarnason K; Cerin A; Lindgren R; Weber T
Maturitas; 1999 Aug; 32(3):161-70. PubMed ID: 10515673
[TBL] [Abstract][Full Text] [Related]
2. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy.
Sturdee DW; Ulrich LG; Barlow DH; Wells M; Campbell MJ; Vessey MP; Nielsen B; Anderson MC; Bragg AJ
BJOG; 2000 Nov; 107(11):1392-400. PubMed ID: 11117768
[TBL] [Abstract][Full Text] [Related]
3. Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study.
Wells M; Sturdee DW; Barlow DH; Ulrich LG; O'Brien K; Campbell MJ; Vessey MP; Bragg AJ
BMJ; 2002 Aug; 325(7358):239. PubMed ID: 12153918
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, multicentre study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms.
Saure A; Hirvonen E; Milsom I; Christensen A; Damber MG
Maturitas; 1996 May; 24(1-2):111-8. PubMed ID: 8794442
[TBL] [Abstract][Full Text] [Related]
5. Norethindrone acetate and estradiol-induced endometrial hyperplasia.
Kurman RJ; Félix JC; Archer DF; Nanavati N; Arce J; Moyer DL
Obstet Gynecol; 2000 Sep; 96(3):373-9. PubMed ID: 10960628
[TBL] [Abstract][Full Text] [Related]
6. Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study.
Samsioe G; Boschitsch E; Concin H; De Geyter C; Ehrenborg A; Heikkinen J; Hobson R; Arguinzoniz M; Ibarra de Palacios P; Scheurer C; Schmidt G;
Climacteric; 2006 Oct; 9(5):368-79. PubMed ID: 17080587
[TBL] [Abstract][Full Text] [Related]
7. Endometrial cancer after combined hormone replacement therapy.
Gruber DM; Wagner G; Kurz C; Sator MO; Huber JC
Maturitas; 1999 Mar; 31(3):237-40. PubMed ID: 10340283
[TBL] [Abstract][Full Text] [Related]
8. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
[TBL] [Abstract][Full Text] [Related]
9. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group.
Archer DF; Furst K; Tipping D; Dain MP; Vandepol C
Obstet Gynecol; 1999 Oct; 94(4):498-503. PubMed ID: 10511348
[TBL] [Abstract][Full Text] [Related]
10. A comparative 2-year study of the effects of sequential regimens of 1 mg 17beta-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women.
Koninckx PR; Spielmann D
Gynecol Endocrinol; 2005 Aug; 21(2):82-9. PubMed ID: 16294460
[TBL] [Abstract][Full Text] [Related]
11. Endometrial response in estrogen replacement therapy quarterly combined with a progestogen.
Boerrigter PJ; van de Weijer PH; Baak JP; Fox H; Haspels AA; Kenemans P
Maturitas; 1996 May; 24(1-2):63-71. PubMed ID: 8794436
[TBL] [Abstract][Full Text] [Related]
12. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium.
Johannisson E; Holinka CF; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():388-98. PubMed ID: 9397386
[TBL] [Abstract][Full Text] [Related]
13. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
[TBL] [Abstract][Full Text] [Related]
14. Bleeding patterns in postmenopausal women using continuous combination hormone replacement therapy with conjugated estrogen and medroxyprogesterone acetate or with 17beta-estradiol and norethindrone acetate.
Odmark IS; Jonsson B; Bäckström T
Am J Obstet Gynecol; 2001 May; 184(6):1131-8. PubMed ID: 11349178
[TBL] [Abstract][Full Text] [Related]
15. Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations.
Skouby SO; Gram J; Andersen LF; Sidelmann J; Petersen KR; Jespersen J
Am J Obstet Gynecol; 2002 May; 186(5):969-77. PubMed ID: 12015523
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled, multicenter study that assessed the endometrial effects of norethindrone acetate plus ethinyl estradiol versus ethinyl estradiol alone.
Portman DJ; Symons JP; Wilborn W; Kempfert NJ
Am J Obstet Gynecol; 2003 Feb; 188(2):334-42. PubMed ID: 12592236
[TBL] [Abstract][Full Text] [Related]
17. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
[TBL] [Abstract][Full Text] [Related]
18. Transdermal hormonal replacement therapy with transdermal progestin every second month.
Lindgren R; Risberg B; Hammar M; Berg G
Maturitas; 1995 Jun; 22(1):25-30. PubMed ID: 7666813
[TBL] [Abstract][Full Text] [Related]
19. Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials.
Rowan JP; Simon JA; Speroff L; Ellman H
Clin Ther; 2006 Jun; 28(6):921-32. PubMed ID: 16860174
[TBL] [Abstract][Full Text] [Related]
20. Unopposed estradiol therapy in postmenopausal women: results from two randomized trials.
Steiner AZ; Xiang M; Mack WJ; Shoupe D; Felix JC; Lobo RA; Hodis HN
Obstet Gynecol; 2007 Mar; 109(3):581-7. PubMed ID: 17329508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
